Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.64 |
| ▸ | IL23R | Q5VWK5 | 11/20 | 0.56 |
| ▸ | NPY4R | P50391 | 7/20 | 0.52 |
| ▸ | NPY1R | P25929 | 6/20 | 0.52 |
| ▸ | NPY2R | P49146 | 6/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12589782 | 1.00 | TFPI (0.64) | TFPIIL23RNPY4RNPY1RNPY2R | |
| SCHEMBL12589785 | 1.00 | TFPI (0.64) | TFPIIL23RNPY4RNPY1RNPY2R | |
| SCHEMBL16348162 | 0.92 | TFPI (0.60) | TFPIIL23RNPY4RNPY1RNPY2R | |
| SCHEMBL13076893 | 0.89 | TFPI (0.57) | TFPIIL23RNPY4RNPY1RNPY2R | |
| SCHEMBL30211355 | 0.89 | NPY4R (0.52) | TFPIIL23RNPY4RNPY1RNPY2R | |
| SCHEMBL30569208 | 0.88 | TFPI (0.59) | TFPIIL23RNPY4RNPY1RNPY2R | |
| SCHEMBL9523164 | 0.87 | TFPI (0.54) | TFPIIL23RNPY4RNPY1RNPY2R | |
| SCHEMBL5049208 | 0.86 | NPY4R (0.59) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30842196 | 0.85 | OPRM1 (0.64) | TFPINPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29502186 | 0.85 | NPY4R (0.52) | TFPINPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524783-B2 | Polymer micelles containing anthracylines for the treatment of cancer | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20100278928-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278928-A1 | POLYMER MICELLES CONTAINING ANTHRACYLINES FOR THE TREATMENT OF CANCER | ABCB4, TOP2A, ANXA5 | TFPI 4758/4885IL23R 3056/4885NPY4R 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.